Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
Public ClinicalTrials.gov record NCT00623766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
Study identification
- NCT ID
- NCT00623766
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 99 participants
Conditions and interventions
Conditions
Interventions
- Ipilimumab Drug
- Corticosteroid: Betamethasone Drug
- Corticosteroid: Dexamethasone Drug
- Corticosteroid: Fludrocortisone Drug
- Corticosteroid: Hydrocortisone Drug
- Corticosteroid: Meprednisone Drug
- Corticosteroid: Methylprednisolone Drug
- Corticosteroid: Prednisolone Drug
- Corticosteroid: Prednisone Drug
- Corticosteroid: Triamcinolone Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2008 (Type not available)
- Primary completion
- Sep 2009 (Actual)
- Completion
- Oct 2012 (Actual)
- Last update posted
- Jun 9, 2014
2008 – 2012
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| City Of Hope | Duarte | California | 91010-3000 | — |
| The Angeles Clinic & Research Institute | Los Angeles | California | 90025 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06520 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Oncology Specialists, S.C. | Park Ridge | Illinois | 60068 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Local Institution | The Bronx | New York | 10466 | — |
| Providence Portland Med Ctr | Portland | Oregon | 97213 | — |
| Vanderbilt-Ingram Cancer Ctr | Nashville | Tennessee | 37232 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00623766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2014 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00623766 live on ClinicalTrials.gov.